EMD Serono Presents New MAVENCLAD® Data Supporting Cognitive Function Benefits
SAN DIEGO, CA / ACCESSWIRE / February 6, 2024 / Rancho Biosciences, a globally recognized Data Science Services company headquartered in San Diego, California, is pleased to announce its partnership with EMD Serono, Takeda and a top 10 pharma company as charter members of the groundbreaking Spatial Innovation Initiative.
Multiple New Analyses Reinforce the Role of BAVENCIO® (avelumab) First-Line Maintenance as a Standard of Care in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
EMD Serono is leaning on drug differentiation in a new digital and social media campaign for Mavenclad, its multiple sclerosis treatment.
EMD Serono Announces Plans for U.S. Healthcare Headquarters in Boston’s District
EMD Serono`s Biologic GONAL-F (follitropin) Receives Approval in the U.S.
EMD Serono to Present Latest Research from Oncology Portfolio at ESMO 2023
Evobrutinib, CNS-Penetrant BTKi, Has Shown Sustained Clinical Benefit Up to Five Years in People with RMS
EMD Serono Presents New MAVENCLAD® (Cladribine) Tablets Data Highlighting Sustained Reduction in NfLs and Benefit of Early Initiation
EMD Serono Launches New Collaboration with United Nations-Guided Global Initiative on Ageing to Support Caregivers